Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Guidance tracker
What GRANULES guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 06 Oct 2026 | Granules India filed the transcript of its webinar "Granules India 2.0 – Comprehensive Transformation Underway", held September 29, 2026, under Regulation 46 of the SEBI LODR Regulations. Dr. Krishna Prasad Chigurupati (CMD) said the company returned to growth in FY26 after nearly three years of flat performance,... NSE copy | +39.2 % | +20.3 % | -2.8 % |
| 27 Jul 2026 | Granules India filed the transcript of its Q1 FY27 earnings conference call held on July 21, 2026, under Regulation 46 of the SEBI LODR Regulations, and uploaded it on its website. Management said Q1 FY27 revenue rose 22% year-on-year to INR1,477 crore, with gross margin at 65.6%, EBITDA up 37% to INR339 crore... NSE copy | +39.2 % | +20.3 % | -2.8 % |
| 05 May 2026 | Granules India filed the transcript of its Q4 and FY26 (year ended March 31, 2026) earnings conference call held April 29, 2026, uploaded on the company website. FY26 revenue stood at INR53,656 million, up 20% year-on-year; Q4 FY26 revenue was INR14,706 million, up 23% year-on-year and 6% sequentially (management... NSE copy | +63.0 % | +22.0 % | -0.0 % |
| 28 Jan 2026 | Granules India filed the transcript of its Q3 and 9M FY26 earnings conference call held on January 23, 2026, uploaded to the company website. Management reported Q3 FY26 revenue of INR13,879 million, up 22% year-on-year and 7% sequentially, with EBITDA of INR3,081 million (22.2% margin) and gross margin of 63.9%.... NSE copy | +32.6 % | +22.8 % | -0.7 % |
| 19 Nov 2025 | Management said the Gagillapur site remediation is in its final stages, with a US FDA meeting granted for January 2026 and reinspection to follow; the Genome Valley GLS site received its first US FDA approval for a product. Q2 FY'26 revenue was Rs. 12,970 million, up 34% year-on-year from Rs. 9,666 million and up... NSE copy | +27.7 % | +22.0 % | +2.5 % |
| 19 Aug 2025 | Granules India filed the transcript of its Q1 FY26 earnings conference call held on August 12, 2025, under Regulation 46 of the SEBI LODR Regulations. Management said remediation at the Gagillapur facility is in its final stages after a US FDA warning letter, with a meeting and re-inspection to be sought in... NSE copy | +34.3 % | +34.2 % | -1.5 % |
| 04 Jun 2025 | Granules India filed the transcript of its Q4 and FY2025 earnings conference call held on May 28, 2025, uploaded to its website. Management said the Gagillapur facility received a US FDA warning letter on February 26, 2025, with remediation slowing operations, impacting Q4 output for another quarter or two. Q4 FY25... NSE copy | -18.0 % | +2.6 % | +3.3 % |
| 30 Jan 2025 | Granules India filed the transcript of its Q3 and 9M FY25 earnings conference call held January 24, 2025. Management said the USFDA classified the August-September 2024 inspection of the Gagillapur facility as Official Action Indicated (OAI), with six Form 483 observations; about 90% of CAPAs are complete and the... NSE copy | +9.4 % | +1.8 % | -1.2 % |
Filings tagged as guidance, newest first (8 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 06 Nov 2026 | Legal or regulatory | Granules India filed the transcript of its Q2 and H1 FY27 earnings conference call held on November 2, 2026, under Regulation 46 of the SEBI LODR Regulations. Management said Q2 revenue grew 20% year-on-year to INR15,600 million and PAT rose 39% year-on-year to INR1,818 million; EBITDA was INR3,376 million, up 21%... NSE copy |
| 27 Jul 2026 | Legal or regulatory | Granules India filed the transcript of its Q1 FY27 earnings conference call held on July 21, 2026, under Regulation 46 of the SEBI LODR Regulations, and uploaded it on its website. Management said Q1 FY27 revenue rose 22% year-on-year to INR1,477 crore, with gross margin at 65.6%, EBITDA up 37% to INR339 crore... NSE copy |
| 28 Jan 2026 | Legal or regulatory | Granules India filed the transcript of its Q3 and 9M FY26 earnings conference call held on January 23, 2026, uploaded to the company website. Management reported Q3 FY26 revenue of INR13,879 million, up 22% year-on-year and 7% sequentially, with EBITDA of INR3,081 million (22.2% margin) and gross margin of 63.9%.... NSE copy |
| 23 Jan 2026 | Credit rating | Granules India filed its Q3FY26 earnings presentation (January 23, 2026), accompanying unaudited results for the quarter and nine months ended December 31, 2025. Q3FY26 revenue was ₹13,879 Mn, up 22% YoY and 7% QoQ; EBITDA was ₹3,081 Mn (22.2% margin) and PAT was ₹1,502 Mn (10.8% of sales). EBITDA included a loss... NSE copy |
| 23 Jan 2026 | Legal or regulatory | Granules India Limited's board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and the board meeting ran from 3.00 PM to 4.40 PM on January 23, 2026. Standalone revenue from operations for Q3 FY26 (quarter ended December 31, 2025) was Rs... NSE copy |
| 23 Dec 2025 | Legal or regulatory | Board of Granules India Limited approved a preferential issue of up to 2,50,00,000 convertible warrants at Rs. 585 per warrant, aggregating up to Rs. 1,462.50 crores, to Promoter group and Non-Promoter investors, convertible into equity shares of Rs. 1 face value within 18 months of allotment. Board also approved a... NSE copy |
| 19 Nov 2025 | Legal or regulatory | Management said the Gagillapur site remediation is in its final stages, with a US FDA meeting granted for January 2026 and reinspection to follow; the Genome Valley GLS site received its first US FDA approval for a product. Q2 FY'26 revenue was Rs. 12,970 million, up 34% year-on-year from Rs. 9,666 million and up... NSE copy |
| 13 Nov 2025 | Legal or regulatory | Granules India filed its Q2FY26 earnings presentation (13 November 2025) alongside unaudited results for the quarter and half year ended 30 September 2025. Q2FY26 revenue was ₹12,970 Mn, up 7% QoQ and 34% YoY; PAT was ₹1,306 Mn (10.1% of revenue), up 16% QoQ and 34% YoY. EBITDA before exceptional items was ₹2,782... NSE copy |
| 19 Aug 2025 | Legal or regulatory | Granules India filed the transcript of its Q1 FY26 earnings conference call held on August 12, 2025, under Regulation 46 of the SEBI LODR Regulations. Management said remediation at the Gagillapur facility is in its final stages after a US FDA warning letter, with a meeting and re-inspection to be sought in... NSE copy |
| 12 Aug 2025 | Legal or regulatory | Granules India filed its Q1 FY26 earnings presentation (August 12, 2025), following its unaudited Q1 FY26 results submitted the same day. Revenue was ₹12,101 Mn, up 3% YoY and 1% QoQ; gross margin was ₹7,850 Mn (64.9%); EBITDA before exceptional items was ₹2,467 Mn (20.4% margin); PAT was ₹1,126 Mn (9.3% margin),... NSE copy |
| 12 Aug 2025 | Legal or regulatory | Board of Granules India Limited approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (meeting held August 12, 2025, 11.00 A.M. to 12.30 P.M.). Consolidated total revenue from operations for Q1 FY26 was Rs 12,101.06 million, versus Rs 11,974.29 million in the previous... NSE copy |
| 04 Jun 2025 | Legal or regulatory | Granules India filed the transcript of its Q4 and FY2025 earnings conference call held on May 28, 2025, uploaded to its website. Management said the Gagillapur facility received a US FDA warning letter on February 26, 2025, with remediation slowing operations, impacting Q4 output for another quarter or two. Q4 FY25... NSE copy |
| 28 May 2025 | Legal or regulatory | Granules India Limited filed an earnings presentation for Q4 FY25 and FY25 on May 28, 2025, following its audited results for the quarter and year ended March 31, 2025. Q4 FY25 revenue was Rs 11,974 Mn, up 1.9% from Rs 11,758 Mn... (Y-o-Y growth shown as 2%), with gross margin at 63.4% and EBITDA of Rs 2,524 Mn... NSE copy |
| 30 Jan 2025 | Legal or regulatory, Management change | Granules India filed the transcript of its Q3 and 9M FY25 earnings conference call held January 24, 2025. Management said the USFDA classified the August-September 2024 inspection of the Gagillapur facility as Official Action Indicated (OAI), with six Form 483 observations; about 90% of CAPAs are complete and the... NSE copy |
| 24 Jan 2025 | Legal or regulatory | Granules India Limited filed its integrated financial filing for the quarter and nine months ended December 31, 2024, including unaudited standalone results (Ind AS, reviewed by S.R. Batliboi & Associates LLP with unmodified review conclusion). Q3 FY25 (quarter ended Dec 31, 2024): total revenue from operations Rs... NSE copy |
| 24 Jan 2025 | Legal or regulatory | Granules India filed an investor/analyst earnings presentation for Q3 FY25 (quarter and nine months ended December 31, 2024), following its unaudited results submitted the same day. Q3 FY25 revenue was Rs 11,377 Mn, up 61.7% year-on-year... [see note] Q3 FY25 gross margin was 61.7%, EBITDA Rs 2,303 Mn (20.2%... NSE copy |
| 24 Jan 2025 | Legal or regulatory | Granules India Limited filed unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, approved by the Board on January 24, 2025, with Limited Review Reports from S.R. Batliboi & Associates LLP. Standalone revenue from operations for Q3 FY25 was Rs 8,421.96... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (17 in all). A list of what was filed, not a judgement of the company.